Advertisement

Topics

Latest Hepatology NewsRSS

11:57 EDT 24th September 2017 | BioPortfolio

Global and Regional Topotecan Hydrochloride Market Research Report 2017 [Report Updated: 11092017] Prices from USD $3500

SummaryTopotecan Hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase IDNA covalent complexes, inhibiting religation of topoisomerase Imediated singlestrand DNA breaks and producing potentially lethal doublestrand DNA breaks when complexes are encounte...

Liver Fibrosis Pipeline Review, H2 2017 [Report Updated: 19092017] Prices from USD $2000

Liver Fibrosis Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis Pipeline Review, H2 2017, provides an overview of the Liver Fibrosis Gastrointestinal pipeline landscape.Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of app...

Global Radioactive Stent Used for Cancer Treatments Market Research Report 20112023 [Report Updated: 25082017] Prices from USD $1800

SummaryRadioactive stent, the selfexpanding stent with radioactivity particles is regards as very useful in the treatment of medium and advanced esoElectronics Softwaregeal cancer.The global Radioactive Stent Used for Cancer Treatments market will reach Volume Million USD in 2017 with CAGR xx% 20182023. The objective of report is to define, segment, and project the market on the basis of product ...

Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib

Opdivo is the first and only Immuno-Oncology agent to receive this FDA approval; this accelerated approval is based on tumor response rate and durability of response in these patients The CheckMate -040 pivotal study evaluated Opdivo in patients with and without active Hepatitis B or C infection, and across PD-L1 expression ...

STAT Plus: Intercept stock rides a roller coaster after FDA note on Ocaliva

Intercept stock fell further after the FDA said the company’s lead drug, Ocaliva, increased the risk of liver injury and death in some patients.

Allergan touts new data from failed NASH study

Cenicriviroc didn't meet the CENTAUR study's primary endpoint, but did show benefit in liver fibrosis.

New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial

DUBLIN, Sept. 22, 2017 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced top-line results from new data for the CENTAUR Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. One year data from the CENTAUR trial was released in 2016. The new data released today includes patients who remained on t...

19 Deaths, Serious Liver Injury Linked to Intercept Pharma's Ocaliva

  Life Sciences Jobs   ...

Elevated Risk for Cholecystitis with Fully Covered vs. Uncovered Metal Biliary Stents

Data confirm previously observed excess risks for cholecystitis and stent migration with covered self-expanding metal stents.

Fatty Liver Disease Global Clinical Trials Review, H2, 2017

LONDON, Sept. 21, 2017 /PRNewswire/ -- Fatty Liver Disease Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2017" provides an overview of Fatty Liver Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Fatty Liver Disease. Report includes an overview of trial...

The Law Offices of John David Hart: Texas Oncology Surgeon Performs Wrong Surgery on Cancer Patient

FORT WORTH, Texas, Sept. 21, 2017 /PRNewswire/ -- Bernice Marie Gomez filed suit against Sujeet Acharya, Texas Oncology, P.A. and Texas Urology Associates in the 160th District Court in and for Dallas County, Texas, Case Number DC-17-12969 on September 20, 2017.  The lawsuit alleges that a Texas Oncology surgeon, Sujeet Acharya, performed the wrong procedure on Ms. Gomez – removi...

Poxel Reports Results for the First Half 2017 and Provides Corporate Update

Poxel will host an investor conference call today to discuss the First Half 2017 results at 1 pm ET (7 pm CET). To participate in the call, please use the dial-in numbers: US: +1 877-887-4163 FR: +33 (0)172001510 UK: +44 2030432440 Access Code: 11730055# POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company fo...

FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease

The Food and Drug Administration (FDA) is warning that the liver disease medicine Ocaliva (obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death.

Cannabliss Retreat To Take Place in Joshua Tree, CA, 9.28.17 - 10.2.17

LOS ANGELES, Sept. 21, 2017 /PRNewswire/ -- Founded by Sari Gabbay, owner of Redefining Cannabis, a cannabis creative agency, Cannabliss Retreat was born with the intention of creating an experience that awakens consciousness and educates the masses about the benefits of cannabis and plant medicines.  Through her passion for awakened consciousness, 14 years+ experience in the lifestyle i...

Image of the Day: 100-Million-Year-Old Flower

Scientists think dinosaurs brushed these ancient flowers into pools of tree resin, creating fossils preserved in amber.

Predictors of Inadequate Bowel Preparation at Colonoscopy (FREE)

Identifying predictors, like constipation, cirrhosis, or diabetes, can be used to triage patients to more-effective preparation regimens.

A Leading Texas Brain Injury Rehabilitation Company Advances Healthcare in the Cleveland Area

Experts in Traumatic Brain Injury and Stroke Rehabilitation Enter Cleveland Market Mentis Neuro Health, industry experts in post-acute rehabilitation for people with acquired brain injuries (ABI), announced today that it is launching its second free-standing outpatient treatment facility in the state of Ohio. The new facility will be located at 6111 Oa...

Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the LEERINK Partners Roundtable Series: Rare Disease and Immuno-Oncology on Wedne...

Norgine BV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryNorgine BV Norgine is a pharmaceutical company that develops pharmaceutical products for diseases with unmet medical needs. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, ...

Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-c...

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2017

LONDON, Sept. 19, 2017 /PRNewswire/ -- Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2017Download the full report: https://www.reportbuyer.com/product/4423614SummaryHistone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an e...

Verity Health Establishes Pancreatic Cancer Program with Thought Leader Oncologist Bringing Expertise in Pancreas and Gastrointestinal Cancers

Pancreatic Cancer and GI Oncologist Tara E. Seery, M.D., Appointed as Director of Pancreatic Cancer at Verity Medical Group and Verity Health System Verity Health, a nonprofit healthcare system, today announced tha

Alcoholism Gene Therapy Shows Promise

Scientists in North and South America have developed a form of gene therapy that could feasibly help to treat alcoholism by causing unpleasant physical side effects in individuals who imbibe. The approach harnesses a short hairpin RNA (shRNA), which is delivered to liver cells using an adeno-associated viral (AAV) vector to prevent expression of a liver enzyme that is involved in metabolizing etha...

Gene Therapy for Treating Alcoholism Shows Promise In Vitro

Scientists in North and South America have developed a form of gene therapy that could feasibly help to treat alcoholism by causing unpleasant physical side-effects in individuals who imbibe. The approach harnesses a short hairpin RNA (shRNA), which is delivered to liver cells using an adeno-associated viral (AAV) vector to prevent expression of a liver enzyme that is involved in metabolizing etha...

Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases

TORONTO, ONTARIO -- (Marketwired) -- 09/19/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will a...

Quick Search
Advertisement
 

review and buy Hepatology market research data and corporate reports here